Dermatologic manifestations in lupus erythematosus;Manifestations dermatologiques du lupus

Revue de Medecine Interne

Volumn 29, Issue 9, 2008, Pages 701-709

  Frances C ^a   Barete S ^a,b   Piette, J C ^b  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cutaneous lupus erythematosus; Dermatologic manifestations; Thrombosis

Indexed keywords

ANTIMALARIAL AGENT; IMMUNOGLOBULIN A;

ALOPECIA; CLINICAL FEATURE; DERMATITIS; DIAGNOSTIC ACCURACY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; PANNICULITIS; PRACTICE GUIDELINE; PSORIASIS; SHORT SURVEY; SKIN BLEEDING; SKIN DISEASE; SKIN NECROSIS; SKIN ULCER; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; URTICARIA; VASCULAR DISEASE; VASCULITIS;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SKIN DISEASES; VASCULAR DISEASES;

EID: 49849095234     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.04.021     Document Type: Short Survey

References (25)

1. Sontheimer R.D. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 4 (2005) 253-263
2. Jiménez S., Cervera R., Ingelmo M., and Font J. The epidemiology of lupus erythematosus. In: Kuhn A., Lehmann P., and Ruzicka T. (Eds). Cutaneous lupus erythematosus (2005), Springer-Verlag, Berlin 33-44
3. Werth V.P., Zhang W., Dortzbach K., and Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 115 (2000) 726-730
4. Boeckler P., Milea M., Meyer A., Uring-Lambert B., Heid E., Hauptmann G., et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 152 (2005) 265-270
5. Kuhn A., Sonntag M., Richter-Hintz D., Oslislo C., Megahed M., Ruzicka T., et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 45 (2001) 86-95
6. Costedoat-Chalumeau N., Amoura Z., Le Thi Hong D., Georgin S., Vauthier D., Sebbouh D., et al. « Lupus néonatal » : revue de la littérature. Rev Med Interne 24 (2003) 659-671
7. Choonhakarn C., Poonsriaram A., and Chaivoramukul J. Lupus erythematosus tumidus. Int J Dermatol 43 (2004) 815-818
8. Viguier M., Pinquier L., Cavelier-Balloy B., de la Salmoniere P., Cordoliani F., Flageul B., et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore) 80 (2001) 180-188
9. Cribier B., Djeridi N., Peltre B., and Grosshans E. A histologic and immunohistochemical study of chilblains. J Am Acad Dermatol 45 (2001) 924-929
10. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725
11. Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 31 (2005) 245-254 vi
12. Specker C., and Schneider M. Relationship between cutaneous and systemic lupus erythematosus. In: Kuhn A., Lehmann P., and Ruzicka Th (Eds). Cutaneous lupus erythematosus (2005), Springer-Verlag, Berlin 177-186
13. Lampropoulos C.E., Sangle S., Harrison P., Hughes G.R., and D'Cruz D.P. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 43 (2004) 1383-1385
14. Kreuter A., Gambichler T., Breuckmann F., Pawlak F.M., Stucker M., Bader A., et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 51 (2004) 407-410
15. van Beek M.J., and Piette W.W. Antimalarials. Dermatol Clin 19 (2001) 147-160 ix
16. Costedoat-Chalumeau N., Amoura Z., Huong du L.T., Lechat P., and Piette J.C. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 4 (2005) 111-115
17. Rigaudiere F., Ingster-Moati I., Hache J.C., Leid J., Verdet R., Haymann P., et al. Surveillance ophtalmologique de la prise des antipaludéens de synthèse au long cours : mise au point et conduite à tenir à partir de 2003. J Fr Ophtalmol 27 (2004) 191-199
18. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Hammoud H.A., et al. Very low blood hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 66 (2007) 821-824
19. Callen J.P. Update on the management of cutaneous lupus erythematosus. Br J Dermatol 151 (2004) 731-736
20. Laffitte E., and Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 3 (2004) 47-56
21. Sabbagh N., Delaporte E., Marez D., Lo-Guidice J.M., Piette F., and Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 7 (1997) 131-135
22. Frances C., and Piette J.C. Cutaneous manifestations of Hughes syndrome occurring in the context of lupus erythematosus. Lupus 6 (1997) 139-144
23. Frances C., Niang S., Laffitte E., Pelletier F., Costedoat N., and Piette J.C. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 52 (2005) 1785-1793
24. Sparsa A., Piette J.C., Wechsler B., Amoura Z., and Frances C. Anetoderma and its prothrombotic abnormalities. J Am Acad Dermatol 49 (2003) 1008-1012
25. Lagrange S., Chosidow O., Piette J.C., Wechsler B., Godeau P., and Frances C. A peculiar form of amicrobial pustulosis of the folds associated with systemic lupus erythematosus and other auto-immune diseases. Lupus 6 (1997) 514-520